CCR2 and cancer: Although anti-CCL2 antibodies and CCR2 antagonists have been tested in clinical trials, one study reported that the interruption of anti-CCL2 antibody treatment markedly increased lung metastasis and accelerated death in mouse syngeneic cancer models [38].